Bempedoic acid (ETC1002) is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid(ETC1002) is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up […]
More Information Supplier Page
TBA-354 is anti-tuberculous and active against Mycobacterium tuberculosis strain H37Rv.
More Information Supplier Page
Dioxopromethazine is a target-based classification of drug and available in a number of countries worldwide.
More Information Supplier Page
Dioxopromethazine is a target-based classification of drug and available in a number of countries worldwide.
More Information Supplier Page
TAS-102 is a novel oral combination drug containing trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
More Information Supplier Page
TAS-102 is a novel oral combination drug containing trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
More Information Supplier Page TAS-102 is a novel oral combination drug containing trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
More Information Supplier Page TBA-354 is anti-tuberculous and active against Mycobacterium tuberculosis strain H37Rv.
More Information Supplier Page 
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.
More Information Supplier Page
